nivolumab
immun
checkpoint
inhibitor
ici
becom
new
treatment
option
malign
tumor
initi
proven
effect
melanoma
diseas
agent
administ
expand
howev
number
immunerel
advers
event
ira
rare
seen
convent
chemotherapi
report
drug
frequenc
use
increas
concern
number
side
effect
also
increas
experienc
case
myocard
induc
nivolumab
knowledg
case
report
case
onset
delay
one
year
introduct
nivolumab
cardiac
magnet
reson
imag
cmr
find
use
differenti
viral
myocard
report
case
review
literatur
man
unresect
lung
adenocarcinoma
clinic
stage
eighth
lung
cancer
stage
classif
diagnos
august
present
saitama
cardiovascular
respiratori
center
complain
back
pain
chest
discomfort
gener
fatigu
dyspnea
septemb
admit
evalu
mild
fibrosi
possibl
interstiti
lung
diseas
ct
could
rule
receiv
chemotherapi
without
radiat
therapi
sinc
diagnosi
adenocarcinoma
sinc
septemb
undergon
chemotherapi
cisplatin
plu
pemetrex
follow
mainten
chemotherapi
pemetrex
docetaxel
may
contralater
mediastin
lymph
node
enlarg
recurr
diagnos
nivolumab
start
biweekli
swollen
lymph
node
decreas
size
abnorm
shadow
note
consid
complet
remiss
novemb
decreas
valu
elev
thyroidstimul
hormon
valu
indic
hypothyroid
found
clinic
symptom
follow
without
treatment
juli
develop
gener
fatigu
consid
symptom
due
hypothyroid
stop
nivolumab
august
gener
fatigu
improv
restart
nivolumab
howev
septemb
day
administr
nivolumab
develop
back
pain
chest
discomfort
gener
fatigu
dyspnea
vital
sign
follow
blood
pressur
mmhg
heart
rate
beatsmin
respiratori
rate
chest
auscult
reveal
irregular
heartbeat
without
murmur
rale
pit
edema
found
lower
extrem
electrocardiogram
show
wide
qr
wave
fig
transthorac
cardiac
ultrasound
examin
show
attenu
left
ventricular
eject
fraction
compar
februari
decreas
left
ventricular
wall
motion
posterior
inferior
later
wall
laboratori
data
show
white
blood
cell
hemoglobin
gdl
platelet
serum
creatin
kinas
valu
iul
normal
increas
creatin
kinasemyocardi
band
ngml
normal
ngml
cardiac
troponin
ngml
normal
ngml
creactiv
protein
valu
also
increas
mgdl
autoantibodi
includ
antinuclear
antibodi
antibodi
antiar
antibodi
antid
dna
antibodi
antirnp
antibodi
antissaro
antissbla
antibodi
neg
bnp
increas
pgml
chest
xray
show
cardiac
enlarg
rightsid
pleural
effus
fig
initi
suspect
acut
myocardi
infarct
swanganz
cathet
insert
assist
manag
intens
care
unit
pulmonari
arteri
pressur
systolicdiastol
mean
mmhg
emerg
coronari
angiographi
perform
signific
stenosi
coronari
arteri
found
also
perform
variou
cmr
examin
fig
cine
imag
show
diffus
moder
reduc
wall
motion
abnorm
mild
wall
hypertrophi
shorttau
invers
recoveri
stir
blackblood
bb
imag
show
diffus
high
signal
intens
si
equal
greater
spleen
si
earli
gadoliniumenhanc
ege
imag
show
diffus
hyperenhanc
myocardium
late
gadoliniumenhanc
imag
show
diffus
patchi
enhanc
given
find
diagnos
myocard
diffus
myocardi
edema
perform
myocardi
biopsi
endocardi
side
left
ventricl
biopsi
reveal
fibrosi
myocardi
tissu
infiltr
inflammatori
cell
celldomin
lymphocyt
infiltr
consist
lymphocyt
myocard
fig
viral
pcr
test
use
myocardi
specimen
influenza
viru
adenoviru
respiratori
syncyti
viru
corona
viru
parainfluenza
viru
bocaviru
echoviru
coxsacki
viru
echoviru
enteroviru
neg
serum
antibodi
measur
convalesc
phase
echoviru
coxsacki
viru
enteroviru
adenoviru
influenza
viru
parainfluenza
viru
respiratori
syncyti
viru
increas
compar
measur
acut
phase
subsequ
consid
nivolumabinduc
myocard
also
detect
transient
complet
atrioventricular
block
myocardi
biopsi
insert
temporari
pacemak
new
find
diagnos
patient
nivolumabinduc
myocard
start
administr
methylprednisolon
g
daili
day
hospit
day
intern
corticosteroid
dose
prednisolon
reduc
mg
daili
mgkg
patient
condit
subsequ
improv
serum
creatin
kinas
valu
decreas
normal
rang
within
week
admiss
eject
fraction
measur
transthorac
cardiac
ultrasound
examin
perform
hospit
day
improv
asynergi
cardiac
wall
also
improv
electrocardiographi
perform
hospit
day
show
narrow
qr
cmr
imag
perform
hospit
day
one
month
follow
start
methylprednisolon
administr
cine
imag
show
gradual
improv
wall
motion
abnorm
recoveri
left
ventricular
eject
fraction
ege
imag
show
improv
edema
find
late
gadolinium
enhanc
myocardium
decreas
patient
discharg
hospit
day
discharg
corticosteroid
dose
gradual
taper
prednisolon
mg
daili
week
mg
daili
week
mg
daili
week
mg
daili
thereaft
regularli
follow
outpati
basi
continu
take
prednisolon
mg
daili
myocard
recur
herein
report
case
nivolumabinduc
myocard
develop
one
year
administr
cardiac
muscl
biopsi
specimen
show
celldomin
lymphocyt
infiltr
success
improv
corticosteroid
therapi
ici
nivolumab
novel
remedi
malign
tumor
promot
attack
cancer
cell
lymphocyt
suppress
express
cell
surfac
cancer
cell
nivolumab
transform
treatment
sever
cancer
releas
restrain
antitumor
immun
respons
treatment
nivolumab
known
caus
sever
ira
includ
thyroid
dysfunct
coliti
pneumon
rare
type
diabet
syndrom
myasthenia
gravi
howev
frequenc
myocard
wherea
frequenc
myocard
due
ici
pembrolizumab
atezolizumab
japan
report
patient
patient
respect
although
probabl
occurr
high
myocard
ira
ignor
due
possibl
fatal
outcom
knowledg
case
myocard
induc
nivolumab
report
tabl
among
case
patient
age
rang
year
men
includ
malign
nivolumab
administ
includ
melanoma
eight
case
lung
cancer
four
case
glioblastoma
one
case
develop
nivolumabinduc
myocard
occur
initi
administr
nivolumab
five
case
second
administr
three
case
third
administr
three
case
ninth
administr
one
case
tenth
administr
one
case
patient
develop
myocard
one
year
initi
nivolumab
third
readministr
twomonth
period
drug
cessat
due
hypothyroid
case
indic
nivolumabinduc
myocard
develop
even
one
year
administr
thu
clinician
consid
nivolumab
caus
myocard
even
one
year
pass
introduct
nine
patient
underw
myocardi
biopsi
autopsi
patient
myocardi
tissu
fibrosi
inflammatori
cell
infiltr
celldomin
lymphocyt
infiltr
find
also
found
patient
previou
report
characterist
histolog
find
nivolumabinduc
myocard
tcell
inflamm
four
potenti
mechan
ira
propos
first
ici
monoclon
antibodi
bind
directli
cell
surfac
protein
cytotox
lymphocyt
antigen
express
normal
tissu
caus
tcell
infiltr
injuri
tissu
due
complement
mediat
second
circul
cell
recogn
antigen
express
tumor
cell
identifi
either
tumor
antigen
homolog
tissu
antigen
healthi
tissu
ici
therapi
inhibit
program
cell
death
protein
stimul
recognit
bind
cell
antigen
express
nontarget
organ
third
evid
suggest
inhibit
immun
checkpoint
molecul
increas
circul
cytokin
level
affect
tissu
thu
help
inflammatori
molecul
infiltr
nontarget
tissu
fourth
antibodi
administ
ici
may
increas
autoantibodi
level
target
organ
stimul
new
autoantibodi
format
cmr
perform
case
show
vari
pattern
includ
diffus
contrast
effect
local
contrast
effect
normal
find
accumul
cmr
find
nivolumabinduc
myocard
need
order
better
determin
characterist
find
case
howev
cmr
use
case
rule
viral
myocard
caus
viral
myocard
usual
affect
epicardium
reflect
hematogen
spread
wherea
patient
show
diffus
myocardi
distribut
cmr
may
use
differenti
viral
myocard
diseas
entiti
consid
mechan
underli
side
effect
ici
describ
steroid
often
administ
counteract
seriou
ira
patient
addit
heart
failur
complet
atrioventricular
block
develop
necessari
administ
steroid
among
case
report
far
none
patient
underw
observ
without
treatment
recent
publish
clinic
practic
guidelin
state
ici
patient
complic
myocard
treat
corticosteroid
regardless
grade
cardiac
toxic
therapeut
option
report
case
includ
prednisolon
methylprednisolon
mycophenol
mofetil
methylprednisolon
infliximab
methylprednisolon
intraven
antithymu
immunoglobulin
mention
therapi
case
corticosteroid
therapi
seem
effect
case
death
patient
treat
steroid
therapi
also
report
one
patient
recurr
myocard
nivolumab
readministr
eventu
die
therefor
consid
nivolumab
readminist
case
conclus
experienc
case
nivolumabinduc
myocard
success
treat
steroid
therapi
evalu
cmr
find
acut
phase
discharg
although
report
nivolumabinduc
myocard
limit
myocard
lifethreaten
advers
event
clinician
consid
differenti
diagnosi
encount
patient
treat
nivolumab
author
state
conflict
interest
coi
